-

Bayer Announces New Commercial Leaders for Crop Science Division to Accelerate Growth and Drive Business Transformation

MONHEIM, Germany--(BUSINESS WIRE)--Bayer today announced that Brett Begemann, Chief Operating Officer, Crop Science, will retire from his role after 38 years with the company.

Rodrigo Santos, currently Head of Crop Science Commercial Operations, Latin America, will succeed Begemann and assume global responsibility for the division’s commercial organization, reporting to Liam Condon, President Crop Science and Board of Management Member at Bayer AG.

Santos’ replacement as Head of Commercial Operations, Crop Science, Latin America, is Mauricio Rodrigues, currently Head of Finance, Crop Science, Latin America.

“The entire Bayer team shares their thanks and appreciation to Brett for everything that he has done throughout his long and successful career at the company, and wish him all the best in his retirement,” said Condon. “We are very pleased to name Rodrigo as Brett’s successor, as he brings extensive experience that will allow us to further strengthen our leadership positions around the world and drive sustainable growth for our customers. Rodrigo is well-known with customers in Latin America and is highly qualified, having led our fastest-growing business while successfully completing integration in a very dynamic region.”

During his tenure with the company, Begemann held several global and regional leadership positions and had responsibility for global commercial and operations teams at Monsanto prior to the acquisition by Bayer. As President and Chief Operating Officer at Monsanto Company, he led global efforts to increase manufacturing and supply chain efficiency, as well as the company’s growth agenda.

Santos, a Brazilian national, has spent over 23 years with the company and has led the Latin American Crop Science business for Bayer since the integration of Monsanto and Bayer in 2018. Earlier in his career, Santos worked in sales, marketing, strategy and business development roles, including a leadership role in Eastern Europe.

Santos graduated with a Bachelor of Science degree in Agricultural Engineering from Escola Superior de Agricultura Luiz de Queiroz – ESALQ/USP and holds a Master of Business Administration from FGV/Ohio University.

Rodrigues, a Brazilian national, has been with the company since 1999, and has held numerous roles in Finance in Brazil, Mexico and the United States, before becoming Head of Finance, Crop Science, for Latin America. He holds a bachelor’s degree in Civil Engineering from Escola Politécnica – POLI/USP, an MBA from Insper and attended the CFO Program at the Wharton School.

The changes are effective June 8, 2021.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.

(2021-0094)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or development.

Contacts

Media Inquiries:

Carly Scaduto, phone +1 314 439 6978
Email: carly.scaduto@bayer.com

Alexander Hennig, phone +49 175 30 89 736
Email: alexander.hennig@bayer.com

Bayer


Release Versions

Contacts

Media Inquiries:

Carly Scaduto, phone +1 314 439 6978
Email: carly.scaduto@bayer.com

Alexander Hennig, phone +49 175 30 89 736
Email: alexander.hennig@bayer.com

More News From Bayer

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a randomized, double-blind, placebo-controlled, group-comparison trial (NCT07211685), with an extension phase, which will investigat...

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane. QUANTI Pediatric evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhanced magnetic resonance imaging (MRI) at a gadolinium dose of 0.04 mmol Gd/kg body weight, representing a dose reduction...

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the treatment of nonatypical endometrial hyperplasia (NAEH) in women. NAEH is an abnormal thickening of the lining of the uterus, known as the endometrium, due to an imbalance between estrogen and progesterone levels. This condition is classified as nonatypical as the cells...
Back to Newsroom